Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
An acute-on-chronic health crisis in Gaza

The Palestinian Gaza Strip is a 365 km² piece of land on the eastern coast of the Mediterranean, inhabited by more than 2 million Palestinians. This open-air enclave has been under siege for the past 14 years, which has left the health system jeopardised by limited resources, failing equipment, and many essential drugs in dangerously low supply. This grim situation was worsened by the arrival of the COVID-19 pandemic, threatening health services with collapse. Beginning on May 9, 2021, the Israeli Government and Hamas launched a military offensive against one another, the severity of which for the Gaza Strip is believed to be the worst since 2014.¹

The background to this situation is important. There has been increasing tension in Israeli-occupied Palestinian East Jerusalem, with Palestinian families living in the Sheikh Jarrah neighbourhood fighting a legal struggle against their eviction.² Tensions grew further at the beginning of the Muslim holy month of Ramadan, with Israel blocking Palestinian gatherings, and with Palestinian worshippers calling for the removal of Israeli police from the al-Aqsa mosque, one of the three holiest sites of Islam where Palestinians pray during Ramadan. In the early morning of May 10, 2021, Israeli forces entered the al-Aqsa mosque while people were praying, with Palestinians injured by rubber bullets and tear gas.³,⁴

In the Gaza Strip, Hamas responded by firing rockets into Israel. Israel responded with strikes by fighter jets and attack helicopters on military targets, which also, and inevitably, included densely populated civilian areas. As of May 18, 2021, Israeli attacks are ongoing, and the Palestinian Ministry of Health has reported at least 212 Palestinians killed, including 36 women and 61 children, and about 1500 Palestinians wounded.⁵,⁶ Hamas rockets have killed ten Israelis, including two children, and wounded at least 300 Israelis.⁷ Hospital emergency departments in Gaza are unable to cope with critical medical conditions, including severe hypovolemic shock, penetrating head, chest, and abdominal injuries, burns, blast injuries, and severe lacerated and fragmented lower limbs. The continuous attacks on dense Gaza urban settings have not only led to the deaths and injuries of civilians but have also left hundreds of people homeless.

We call upon world leaders to intervene for an immediate de-escalation of attacks by both the Israeli Government and Hamas and to end the violence, protect civilians from political violence in the Gaza Strip and the West Bank, and protect civilians in Israel. We also call for renewed international action to deliver justice, freedom, and self-determination for Palestinians.

We declare no competing interests.

Issam Awadallah, “Khamis Elessi
khamis_essi@yahoo.com
Shifa Medical Complex, Gaza Strip, Palestine (IA); Neuro-rehabilitation and Pain Medicine, Faculty of Medicine, Islamic University, Gaza Strip, Palestine (KE)

1. Shehadeh R, Shehjar Jarrah and the renewed Israeli-Palestinian violence. May 11, 2021. https://www.newyorker.com/news/daily-comment/sheik-jarrah-and-the-renewed-israeli-palestinian-violence (accessed May 15, 2021).
2. Kingsley P. Evictions in Jerusalem become focus of Israeli-Palestinian conflict. May 7, 2021. https://www.nytimes.com/2021/05/07/world/middleeast/evictions-jerusalem-israeli-palestinian-conflict-protest.html (accessed May 15, 2021).
3. Middle East Eye staff. Al-Aqsa: Israeli forces storm the complex ahead of far-right procession. May 10, 2021. https://www.middleeasteye.net/news/israel-palestine-jerusalem-al-aqsa-wounded-raid-old-city-procession (accessed May 15, 2021).
4. AFP. Timeline: deadly Gaza and Jerusalem clashes. May 11, 2021. https://www.france24.com/en/live-news/20210511-timeline-deadly-gaza-and-jerusalem-clashes. (accessed May 15, 2021).
5. Palestinian Ministry of Health. Developments of the ongoing Israeli attacks on the Gaza Strip—day 8. May 17, 2021. https://www.moh.gov.ps/portal/developments-of-the-ongoing-israeli-attacks-on-the-gaza-strip-day-8 (accessed May 18, 2021).
6. Mayberry K, Pietromarchi V. Israeli air raids hit Gaza as US ‘supports ceasefire’. May 18, 2021. https://www.aljazeera.com/online/online/newswire/2021/5/18/ israel-shells-lebanon-as-biden-continues-push-for-gaza-ceasefire (accessed May 18, 2021).

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

There is significant international interest in heterologous prime-boost COVID-19 vaccination to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out. Additionally, in light of changing recommendations regarding use of the ChAdOx1 nCoV-19 (ChAd) COVID-19 vaccine (Vaxzevria, AstraZeneca), several countries are now advising that individuals previously primed with this vaccine should now receive an alternative vaccine as their second dose, most commonly mRNA vaccines such as the BNT162b2 (BNT) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech), administered in a heterologous prime-boost schedule.¹² To date there are no data on the immunogenicity, reactogenicity, or safety of such schedules. Com-COV (ISRCTN 69254139) is a UK multicentre, participant-masked, randomised heterologous prime-boost COVID-19 vaccination study comparing all four prime-boost permutations of the ChAd and BNT vaccines both at 28-day and 84-day prime-boost intervals. Participants are 50 years and older with no or mild-to-moderate, well controlled comorbidity and were recruited across eight sites. The protocol is available online.

Following consultation with the study trial steering committee, here we present the initial reactogenicity and safety data, ahead of the primary immunological outcome, which is projected to be available in June, 2021. Reactogenicity data presented here consist of self-reported solicited local and systemic symptoms collected in the 7 days after both prime and boost vaccination in participants randomised to receive vaccines at 28-day intervals. Haematology and biochemistry safety monitoring blood results are also reported from the immunology cohort.

For the Com-COV protocol see https://comcovstudy.org.uk/study-protocol

Published Online
May 18, 2021
https://doi.org/10.1016/S0140-6736(21)01158-2

Published Online
May 12, 2021
https://doi.org/10.1016/S0140-6736(21)01115-6

For the Com-COV protocol see https://comcovstudy.org.uk/study-protocol

This online publication has been corrected. The corrected version first appeared at thelancet.com on May 21, 2021

This online publication has been corrected. The corrected version first appeared at thelancet.com on May 18, 2021
(100 participants with additional visits), at baseline (before the prime dose), at day 28 (before the boost dose) and 7 days post-boost, graded according to a modified US Food and Drug Administration toxicity scale (appendix). All analyses are descriptive, as the study was not powered for reactogenicity, with endpoints reported as frequencies and percentages, together with absolute differences between heterologous and homologous vaccine schedules and corresponding 95% CIs.

Recruitment commenced on Feb 11, 2021, and was completed on Feb 26, 2021, with 830 participants enrolled and randomised from 928 screened (the CONSORT flow diagram is available in the appendix). 463 participants were randomly assigned to the four groups with a 28-day prime-boost interval, and 367 participants randomised to groups with an 84-day prime-boost interval. All 463 participants in the 28-day prime-boost interval group received their prime vaccine, and 461 participants received their boost vaccine. Among the 463 participants, the median age was 57 years (range 50–69), 212 (46%) participants were female, and 117 (25%) from ethnic minorities, with baseline characteristics well balanced across study groups.

In groups with homologous vaccine schedules, systemic reactogenicity was greater after the prime dose in the ChAd group, and after the boost dose in the BNT group (figure).

Both heterologous vaccine schedules induced greater systemic reactogenicity following the boost dose than their homologous counterparts, with feverishness reported by 37 (34%) of 110 recipients of ChAd for prime and BNT for boost compared with 11 (10%) of 112 recipients of ChAd for both prime and boost (difference 24%, 95% CI 13–35%). Feverishness was reported by 47 (41%) of 114 recipients of BNT for prime and ChAd for boost, compared with 24 (21%) of 112 recipients of BNT for both prime and boost (difference 21%, 95% CI 8–33%). Similar increases were observed for chills, fatigue, headache, joint pain, malaise, and muscle ache (figure; appendix). There were no hospitalisations due to solicited symptoms, and most of this increase in reactogenicity was observed in the 48 h after immunisation (appendix).

Participants were advised that paracetamol might reduce vaccine side-effects but were not actively counselled to medicate prophylactically. Paracetamol use in the 48 h post-boost vaccine was reported by 40 (36%) of 112 recipients of ChAd for both prime and boost, 63 (57%) of 110 recipients of ChAd for prime and BNT for boost, 48 (41%) of 117 recipients of BNT for both prime and boost, and 68 (60%) of 114 recipients of BNT for prime and ChAd for boost, thereby mirroring the reactogenicity pattern.

Haematology and biochemistry profiles were similar between heterologous and homologous vaccine schedules, with all laboratory adverse events of grade 2 severity or less in the heterologous vaccine schedule, and no thrombocytopenia in any group at day 7 post-boost (appendix).

In this interim safety analysis, we found an increase in systemic reactogenicity after the boost dose reported by participants in heterologous vaccine schedules in comparison to homologous vaccine schedules, and this was accompanied by increased paracetamol usage. Of note, these data were obtained in participants aged 50 years and older, and reactogenicity might be higher in younger age groups for whom a mixed vaccination schedule is being advocated in Germany, France, Sweden, Norway, and Denmark among those who have received a ChAd prime dose, in light of concerns regarding thrombotic thrombocytopenia after the first dose of ChAd.

Pending availability of a more complete safety dataset and immunogenicity results for heterologous prime-boost schedules (to be reported shortly), these data suggest that the two heterologous vaccine schedules in this trial might have some short-term disadvantages. Routine prophylactic use of paracetamol after immunisation could help mitigate these and is being studied in Com-COV participants receiving prime and boost vaccines at 12-week intervals. Regardless, it is reassuring that all reactogenicity symptoms were short lived, and there were no concerns from the limited haematology and biochemistry data available. Further studies evaluating heterologous prime-boost schedules, incorporating vaccines manufactured by Moderna and Novavax, are ongoing, and are crucial to informing the appropriateness of mixed COVID-19 vaccine schedules.

MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM vaccines. He receives no personal financial payment for this work. All other authors declare no competing interests. RHS and AS contributed equally. Members of the Com-COV study group are listed in the appendix.

Robert H Shaw, Arabella Stuart, Melanie Greenland, Xinxue Liu, Jonathan S Nguyen Van-Tam, Matthew D Snape, and the Com-COV Study Group

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK (RHS, AS, MG, XL, MDS); NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (MDS); Division of
A global compact to counter vaccine nationalism

Vaccine nationalism threatens to turn the triumph of science to give the world vaccines against COVID-19 into tragedy. The success of several initiatives, many funded by taxpayers, to rapidly develop and test several safe and effective vaccines has been nothing short of spectacular. The social promise of SARS-CoV-2 vaccines was to reduce the underlying inequalities by race, ethnicity, and geography that COVID-19 has both made visible and amplified. Yet, most of the billion vaccine doses administered have been in high-income countries (HICs), with most low-income and middle-income countries (LMICs) left behind (appendix). WHO and Gavi, the Vaccine Alliance have created COVAX to finance SARS-CoV-2 vaccines for LMICs, yet supply of vaccines is still short and coming from only a few companies. India’s mostly uncontrolled second viral wave threatens exports of vaccines promised to many countries. The US Government suspending its objections to COVID-19 vaccine patents could help. However, the priority is to produce sufficient quantities on an urgent basis to provide global coverage. Aspirations to return to some sense of normality might well remain wishful thinking until most adults globally are vaccinated. How do we do that? We propose an integrated three-pillar global vaccine compact to expand vaccine supply and counter vaccine nationalism. Global vaccine production capacity in non-pandemic times is too small and too concentrated in a handful of pharmaceutical companies. The first pillar of our proposed compact would be for countries to adopt the idea of universal access to life-saving vaccines.

Published Online
May 14, 2021
https://doi.org/10.1016/S0140-6736(21)01105-3

For more on vaccines administered see https://ourworldindata.org/covid-vaccinations

For more on COVAX see https://www.who.int/initiatives/act-accelerator/about

For more on annex see https://covid-vaccinations/administered/accelerator/about

Epidemiology and Public Health, School of Clinical Sciences, University of Nottingham, Nottingham, UK (JSNV-T)

1 Folkhälsomyndigheten - Public Health Agency of Sweden. Information on the continued use of the Astra Zeneica vaccine in the vaccination of people 65 and older. March 26, 2021. http://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/-vaccine-vaccination-against-covid-19/information-on-the-continued-use-of-the-astra-zeneica/ (accessed April 29, 2021).

2 Haute Autorité de Santé - French National Health Authority. Covid-19: quelle stratégie vaccinale pour les moins de 55 ans ayant déjà reçu une dose d’AstraZeneica? April 9, 2021. https://www.has-sante.fr/jcms/p_326035/jes/vac/covid-19-quel-savoir-vaccinat-
pour-les-moins-de-55-ans-ayant-deja-recu-une-dose-d-astraZeneica (accessed April 29, 2021).

3 Sundhedsstyrelsen - Danish Health Authority. Denmark continues its vaccine rollout without AstraZeneica. April 14, 2021. https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19/astraZeneica-vaccine-paused (accessed April 29, 2021).

4 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl Med 2020; 383: 2603–15.

5 Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COVID02): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396: 1979–93.

6 European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. April 7, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood-platelets. April 7, 2021. https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19/astraZeneica-vaccine-paused (accessed April 14, 2021. https://www.sst.dk/en/english/corona-eng/vaccination-against-covid-19/astraZeneica-vaccine-paused (accessed April 14, 2021).

7 Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2021; 396: 463–78.